Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 16
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Impact of very early antiretroviral therapy during acute HIV infection on long-term immunovirological outcomes

  • Suanzes, Paula|||0000-0002-6871-0098
  • Navarro, Jordi|||0000-0002-7187-0367
  • Rando-Segura, Ariadna|||0000-0003-4555-7286
  • Álvarez-López, Patricia|||0000-0003-4227-1987
  • García Pérez, Jorge Néstor|||0000-0003-4986-6094
  • Descalzo Jorro, Vicente
  • Monforte-Pallarés, Arnau|||0000-0002-5468-3885
  • Arando, Maider|||0000-0003-2020-4193
  • Rodríguez Vázquez, Lucía|||0000-0003-0151-3142
  • Planas, Bibiana|||0000-0002-1490-7127
  • Burgos, Joaquín|||0000-0001-8445-3047
  • Curran, Adrian|||0000-0002-1263-0814
  • Buzón, Maria José|||0000-0003-4427-9413
  • Falcó, Vicenç|||0000-0001-9626-0023
Objectives: We aimed to determine if starting antiretroviral therapy (ART) in the first 30 days after acquiring HIV infection has an impact on immunovirological response. Methods: Observational, ambispective study including 147 patients with confirmed acute HIV infection (January/1995-August/2022). ART was defined as very early (≤30 days after the estimated date of infection), early (31-180 days), and late (>180 days). We compared time to viral suppression (viral load [VL] <50 copies/ml) and immune recovery (IR) (CD4+/CD8+ ratio ≥1) according to the timing and type of ART using survival analysis. Results: ART was started in 140 (95.2%) patients. ART was very early in 24 (17.1%), early in 77 (55.0%), and late in 39 (27.9%) cases. Integrase strand transfer inhibitor (INSTI)-based regimens were the most used in both the overall population (65%) and the very early ART group (23/24, 95.8%). Median HIV VL and CD4+/CD8+ ratio pre-ART were higher in the very early ART group (P <0.05). Patients in the very early and early ART groups and treated with INSTI-based regimens achieved IR earlier (P <0.05). Factors associated with faster IR were the CD4+/CD8+ ratio pre-ART (hazard ratio: 9.3, 95% CI: 3.1-27.8, P <0.001) and INSTI-based regimens (hazard ratio: 2.4, 95% CI: 1.3-4.2, P = 0.003). Conclusions: The strongest predictors of IR in patients who start ART during AHI are the CD4+/CD8+ ratio pre-ART and INSTI-based ART regimens.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Early antiretroviral therapy shapes the immunometabolic landscape without reducing the intact HIV reservoir

  • Suanzes, Paula|||0000-0002-6871-0098
  • Grau Expósito, Judith|||0000-0001-9350-2429
  • Navarro, Jordi|||0000-0002-7187-0367
  • Chafino, Silvia
  • Rull, Anna|||0000-0002-8907-7754
  • Rando-Segura, Ariadna|||0000-0003-4555-7286
  • Álvarez-López, Patricia|||0000-0003-4227-1987
  • Descalzo Jorro, Vicente
  • García Pérez, Jorge Néstor|||0000-0003-4986-6094
  • Monforte-Pallarés, Arnau|||0000-0002-5468-3885
  • Curran, Adrian|||0000-0002-1263-0814
  • Burgos, Joaquín|||0000-0001-8445-3047
  • Planas, Bibiana|||0000-0002-1490-7127
  • Sanchiz Cruz, Marta|||0000-0002-6727-428X
  • Genescà Ferrer, Meritxell|||0000-0001-6413-3812
  • Falcó, Vicenç|||0000-0001-9626-0023
  • Buzón, Maria José|||0000-0003-4427-9413
Objectives: We assessed the effect of early ART during acute HIV infection on reservoir dynamics, cytokine profile, and T-cell metabolism. Methods: We studied a longitudinal cohort of PWH starting ART during early (ET) or chronic (CT) infection, and a cross-sectional cohort including matched ET and CT participants (≥36 months virologically suppressed) and HIV-negative controls. We analysed total HIV-DNA, intact and defective proviruses, cell-associated HIV-RNA, plasma cytokines, and metabolomic profiles of CD4+ and CD8+T-cells. Results: Over 75% of ET participants started ART in Fiebig stages IV-VI. Early ART was associated with lower total HIV-DNA and cell-associated RNA. Although intact proviruses were similar between groups, they represented a larger proportion of the reservoir in ET participants. Worse pre-ART immune status correlated with a larger and more transcriptionally active reservoir. Regulatory, inflammatory, and homeostatic cytokines negatively correlated with the intact reservoir, particularly in CT participants. Metabolomic profiling of T-cells demonstrated ART timing-dependent alterations in several metabolic pathways. Metabolites involved in glycolysis, amino-acid metabolism, and polyol pathways positively correlated with HIV transcription in CD4⁺T-cells, especially in CT participants. Conclusion: Early ART limits the HIV reservoir size, shapes its composition, and influences immunometabolic pathways, though it might not be enough to reduce the intact reservoir.
IRTA Pubpro. Open Digital Archive
Publicación Artículo científico (JournalArticle)

Schlafen 12 restricts HIV-1 latency reversal by a codon-usage dependent post-transcriptional block in CD4+ T cells

  • Kobayashi-Ishihara, Mie
  • Frazão Smutná, Katarína
  • Alonso, Florencia E.
  • Argilaguet, Jordi
  • Esteve-Codina, Anna
  • Geiger, Kerstin
  • Genescà, Meritxell
  • Grau-Expósito, Judith
  • Duran-Castells, Clara
  • Rogenmoser, Selina
  • Böttcher, René
  • Jungfleisch, Jennifer
  • Oliva, Baldomero
  • Martinez, Javier P.
  • Li, Manqing
  • David, Michael
  • Yamagishi, Makoto
  • Ruiz-Riol, Marta
  • Brander, Christian
  • Tsunetsugu-Yokota, Yasuko
  • Buzon, Maria J.
  • Díez, Juana
  • Meyerhans, Andreas
Latency is a major barrier towards virus elimination in HIV-1-infected individuals. Yet, the mechanisms that contribute to the maintenance of HIV-1 latency are incompletely understood. Here we describe the Schlafen 12 protein (SLFN12) as an HIV-1 restriction factor that establishes a post-transcriptional block in HIV-1-infected cells and thereby inhibits HIV-1 replication and virus reactivation from latently infected cells. The inhibitory activity is dependent on the HIV-1 codon usage and on the SLFN12 RNase active sites. Within HIV-1-infected individuals, SLFN12 expression in PBMCs correlated with HIV-1 plasma viral loads and proviral loads suggesting a link with the general activation of the immune system. Using an RNA FISH-Flow HIV-1 reactivation assay, we demonstrate that SLFN12 expression is enriched in infected cells positive for HIV-1 transcripts but negative for HIV-1 proteins. Thus, codon-usage dependent translation inhibition of HIV-1 proteins participates in HIV-1 latency and can restrict the amount of virus release after latency reversal., We thank Drs Yingying Li, Feng Gao and Beatrice H. Hahn for providing codon-optimized HIV-1 Gag expression vector, Drs James Hoxie and Susan Zolla-Pazner for supplying anti-Nef and -p24 antibodies, respectively through the NIH AIDS reagent program. We also thank Dr Song Gao for providing SLFN13-tRNA structure information, and Dr Maria-Eugenia Gas Lopez and Dr Ester Gea-Mallorquí for advise. This work was supported by following grants: M.K.I., JSPS Oversea Research Fellowship and Takeda Science Foundation; A.E.C., PT17/0009/0019 (ISCIII/MINECO and FEDER); M.J.B., RTI2018-101082-B-I00 and PID2021-123321OB-I00 [MINECO/FEDER]), and the Miguel Servet program by ISCIII (CP17/00179 and CPII22/00005); C.B., M.R.R., C.D.C., European Union’s Horizon 2020 research and innovation program under grant agreement 681137-EAVI2020 and NIH grant P01-AI131568; J.D., the Spanish Ministry of Science and Innovation (PID2019106959RB-I00/AEI/10.13039/501100011033); A.M., the Spanish Ministry of Science and Innovation (PID2019-106323RB-I00 AEI//10.13039/501100011033) and the institutional “María de Maeztu” Programme for Units of Excellence in R&D (CEX2018-000792-M)., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Schlafen 12 restricts HIV-1 latency reversal by a codon-usage dependent post-transcriptional block in CD4+ T cells

  • Kobayashi-Ishihara, Mie
  • Frazão Smutná, Katarína
  • Alonso, Florencia E.
  • Argilaguet, Jordi
  • Esteve-Codina, Anna
  • Geiger, Kerstin
  • Genescà, Meritxell
  • Grau-Expósito, Judith
  • Duran-Castells, Clara
  • Rogenmoser, Selina
  • Böttcher, René
  • Jungfleisch, Jennifer
  • Oliva, Baldomero
  • Martinez, Javier P.
  • Li, Manqing
  • David, Michael
  • Yamagishi, Makoto
  • Ruiz-Riol, Marta
  • Brander, Christian
  • Tsunetsugu-Yokota, Yasuko
  • Buzon, Maria J.
  • Díez, Juana
  • Meyerhans, Andreas
Latency is a major barrier towards virus elimination in HIV-1-infected individuals. Yet, the mechanisms that contribute to the maintenance of HIV-1 latency are incompletely understood. Here we describe the Schlafen 12 protein (SLFN12) as an HIV-1 restriction factor that establishes a post-transcriptional block in HIV-1-infected cells and thereby inhibits HIV-1 replication and virus reactivation from latently infected cells. The inhibitory activity is dependent on the HIV-1 codon usage and on the SLFN12 RNase active sites. Within HIV-1-infected individuals, SLFN12 expression in PBMCs correlated with HIV-1 plasma viral loads and proviral loads suggesting a link with the general activation of the immune system. Using an RNA FISH-Flow HIV-1 reactivation assay, we demonstrate that SLFN12 expression is enriched in infected cells positive for HIV-1 transcripts but negative for HIV-1 proteins. Thus, codon-usage dependent translation inhibition of HIV-1 proteins participates in HIV-1 latency and can restrict the amount of virus release after latency reversal., We thank Drs Yingying Li, Feng Gao and Beatrice H. Hahn for providing codon-optimized HIV-1 Gag expression vector, Drs James Hoxie and Susan Zolla-Pazner for supplying anti-Nef and -p24 antibodies, respectively through the NIH AIDS reagent program. We also thank Dr Song Gao for providing SLFN13-tRNA structure information, and Dr Maria-Eugenia Gas Lopez and Dr Ester Gea-Mallorquí for advise. This work was supported by following grants: M.K.I., JSPS Oversea Research Fellowship and Takeda Science Foundation; A.E.C., PT17/0009/0019 (ISCIII/MINECO and FEDER); M.J.B., RTI2018-101082-B-I00 and PID2021-123321OB-I00 [MINECO/FEDER]), and the Miguel Servet program by ISCIII (CP17/00179 and CPII22/00005); C.B., M.R.R., C.D.C., European Union’s Horizon 2020 research and innovation program under grant agreement 681137-EAVI2020 and NIH grant P01-AI131568; J.D., the Spanish Ministry of Science and Innovation (PID2019106959RB-I00/AEI/10.13039/501100011033); A.M., the Spanish Ministry of Science and Innovation (PID2019-106323RB-I00 AEI//10.13039/501100011033) and the institutional “María de Maeztu” Programme for Units of Excellence in R&D (CEX2018-000792-M)., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Schlafen 12 restricts HIV-1 latency reversal by a codon-usage dependent post-transcriptional block in CD4+ T cells

  • Kobayashi-Ishihara, Mie
  • Frazão Smutná, Katarína
  • Alonso, Florencia E.
  • Argilaguet, Jordi
  • Esteve-Codina, Anna
  • Geiger, Kerstin
  • Genescà Ferrer, Meritxell
  • Grau Exposito, Judith
  • Buzon, Maria Jose
HIV infections; Restriction factors, Infecciones por VIH; Factores de restricción, Infeccions pel VIH; Factors de restricció, Latency is a major barrier towards virus elimination in HIV-1-infected individuals. Yet, the mechanisms that contribute to the maintenance of HIV-1 latency are incompletely understood. Here we describe the Schlafen 12 protein (SLFN12) as an HIV-1 restriction factor that establishes a post-transcriptional block in HIV-1-infected cells and thereby inhibits HIV-1 replication and virus reactivation from latently infected cells. The inhibitory activity is dependent on the HIV-1 codon usage and on the SLFN12 RNase active sites. Within HIV-1-infected individuals, SLFN12 expression in PBMCs correlated with HIV-1 plasma viral loads and proviral loads suggesting a link with the general activation of the immune system. Using an RNA FISH-Flow HIV-1 reactivation assay, we demonstrate that SLFN12 expression is enriched in infected cells positive for HIV-1 transcripts but negative for HIV-1 proteins. Thus, codon-usage dependent translation inhibition of HIV-1 proteins participates in HIV-1 latency and can restrict the amount of virus release after latency reversal., This work was supported by following grants: M.K.I., JSPS Oversea Research Fellowship and Takeda Science Foundation; A.E.C., PT17/0009/0019 (ISCIII/MINECO and FEDER); M.J.B., RTI2018-101082-B-I00 and PID2021-123321OB-I00 [MINECO/FEDER]), and the Miguel Servet program by ISCIII (CP17/00179 and CPII22/00005); C.B., M.R.R., C.D.C., European Union’s Horizon 2020 research and innovation program under grant agreement 681137-EAVI2020 and NIH grant P01-AI131568; J.D., the Spanish Ministry of Science and Innovation (PID2019106959RB-I00/AEI/10.13039/501100011033); A.M., the Spanish Ministry of Science and Innovation (PID2019-106323RB-I00 AEI//10.13039/501100011033) and the institutional “María de Maeztu” Programme for Units of Excellence in R&D (CEX2018-000792-M).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

NK cell depletion in bispecific antibody therapy is associated with lack of HIV control after ART interruption

  • Perea Pérez, David
  • Martin-Gayo, Enrique
  • Zamora Carrillo, Jorge Ivan
  • Sánchez Gaona, Nerea
  • Curran, Adrian
  • Burgos, Joaquin
  • Navarro, Jordi
  • Suanzes, Paula
  • Falcó, Vicenç
  • Genescà Ferrer, Meritxell
  • Buzon, Maria Jose
NK cell; Bispecific antibody therapy; HIV, Cèl·lules NK; Teràpia d'anticossos biespecífics; VIH, Células NK; Terapia d'anticuerpos biespecíficos; VIH:es, HIV infection remains incurable as the virus persists within a latent reservoir of CD4+T cells. Novel approaches to enhance immune responses against HIV are essential for effective control and potential cure of the infection. In this study, we designed a novel tetravalent bispecific antibody (Bi-Ab32/16) to simultaneously target the gp120 viral protein on infected cells, and the CD16a receptor on NK cells. In vitro, Bi-Ab32/16 triggered a potent, specific, and polyfunctional NK-dependent response against HIV-infected cells. Moreover, addition of the Bi-Ab32/16 significantly reduced the latent HIV reservoir after viral reactivation and mediated the clearance of cells harboring intact proviruses in samples from people with HIV (PWH). However, the in vivo preclinical evaluation of Bi-Ab32/16 in humanized mice expressing IL-15 (NSG-Hu-IL-15) revealed a significant decline of NK cells associated with poor virological control after ART interruption. Our study underscores the need to carefully evaluating strategies for sustained NK cell stimulation during ART withdrawal., This study was supported by the Spanish Secretariat of Science and Innovation, FEDER funds (RTI2018-101082-B-I00, PID2021-123321OB-I00, PDC2022.133836-100), two Gilead fellowships (GLD21/00049, GLD22/00152) as well as partially funded by the PI20/00160 grant from the Spanish Health Institute Carlos III, co-funded by ERDF/ESF, “A way to make Europe”/“Investing in your future”, the CNS2022-135549 grant, funded by MCIN/AEI/10.13039/501100011033 and by the European Union «Next Generation EU»/PRTR. M.B. is supported by the Miguel Servet program funded by the Spanish Health Institute Carlos III (CP17/00179 and CPII22/00005). N.S-G is supported by the Spanish Secretariat of Science and Innovation Ph.D. fellowship (PRE2019-087393). We would like to thank Dr. Julia G. Prado from IrsiCaixa Institute for AIDS Research for generating the viral stock R5-BaL and Jorge Díaz from the Comparative Medicine and Bioimage Centre of Catalonia (CMCIB) for its excellent technical assistance with in vivo animal studies. The funders had no role in study design, data collection, and analysis, the decision to publish, or preparation of the manuscript.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Resident CD49a+CD103+NKG2C+ NK cells restrict HIV infection in human lymphoid tissue explants

  • González Robles, Alba
  • Gallego-Cortés, Ana
  • Ortiz Laredo, Nuria
  • Llano, Ines
  • Perea Pérez, David
  • Sánchez Gaona, PhD, Nerea
  • Pumarola, Felix
  • Lorente, Juan
  • Falcó, Vicenç
  • Genescà Ferrer, Meritxell
  • Buzon, Maria Jose
HIV infection; NK cells, Infección por VIH; Células NK, Infecció per VIH; Cèl·lules NK, Natural killer (NK) cells are pivotal effectors in antiviral immunity, yet their tissue-specific roles during acute HIV infection remain poorly defined. Using an ex vivo human tonsillar tissue model, we profile NK cell responses to early HIV infection and uncover distinct subsets with specialized functions. We identify a previously uncharacterized memory-like NK population (CD16+/−CD69+CD49a+CD103+NKG2C+) associated with reduced viral burden and enriched in cytotoxic mediators (GNLY, PRF1, and GZMB), apoptotic ligands (FASLG and TRAIL), cytokine receptors (IL2RA, IL2RB, IL2RG, IL12RB2, and IL18R1) and trafficking molecules (CCL3–5, CCR7, and SELL). Although functionally capable of clearing HIV-infected CD4+ T cells in a tissue-mimetic environment, they show impaired cytotoxicity and transcriptional signs of exhaustion after infection. Conversely, HIV drives the reprogramming of immature CD16−CD69+ NK cells toward a more cytotoxic and migratory effector phenotype. These findings reveal dynamic NK cell adaptations in lymphoid tissue during early HIV infection and highlight tissue-resident NK cells as promising targets for immunotherapeutic intervention., The project leading to these results has received funding from “la Caixa” Banking Foundation under the project code [LCF/PR/HR20-00218] to M.J.B. This study was supported by the Agencia Estatal de Investigación project PID2021-123321OB-I00 funded by MCIN/AEI/10.13039/501100011033/FEDER, UE to M.J.B.; the Spanish “Ministerio de Economía y Competitividad, Instituto de Salud Carlos III” (ISCIII, PI20/00160) to M.G.; and the Gilead fellowship GLD22/00152 to M.J.B. M.J.B. is supported by the Miguel Servet program funded by the Spanish Health Institute Carlos III (CPII22/00005). D.P. was supported by the VHIR 2020 Ph.D. Fellowship. The funders had no role in study design, data collection, and analysis, the decision to publish, or preparation of the manuscript.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Identification of inducible HIV reservoirs in tonsillar, intestinal and cervical tissue models of HIV latency

  • Gallego-Cortés, Ana
  • Sánchez Gaona, PhD, Nerea
  • Ruiz Isant, Oriol
  • Pumarola, Felix
  • Ortiz Laredo, Nuria
  • Llano Espinosa, Ines
  • Mañalich-Barrachina, Laura
  • Mancebo Pérez, Cristina
  • Benítez Martínez, Aleix
  • Landolfi, Stefania
  • Castellvi, Josep
  • Lorente, Juan
  • Falcó, Vicenç
  • Genescà Ferrer, Meritxell
  • Buzon, Maria Jose
HIV; Tissue models; Cellular reservoirs, VIH; Modelos de tejido; Reservorios celulares, VIH; Models de teixit; Reservoris cel·lulars, HIV persists in diverse tissues, with distinct cellular reservoirs presenting a major barrier to a cure and requiring targeted therapeutic strategies to address this heterogeneity. Here, we develop tissue models of HIV latency using human tonsillar, intestinal and cervicovaginal tissues. These models reveal differential HIV infection across CD4+ T-cell subpopulations, with ART partially restoring CD4+ T cells and reducing intact HIV DNA. T follicular helper cells (TFH CD69+ CCR7-) are the primary inducible reservoir in tonsils, while tissue-resident memory cells (TRM CD69+ CD49a+) dominate in the intestine. Identification of markers for inducible reservoirs shows that CD69, CD45RO, and PD-1 are shared across tissues, while CXCR5 in tonsils and CD49a in the intestine act as tissue-specific markers. Furthermore, using different latency reversal agents (LRAs) demonstrates that Histone Deacetylase Inhibitors (HDACis) fail to induce HIV in any tissue, the SMAC mimetic AZD5582 is effective only in a resident-memory CD4+ T-cell subpopulation in the intestine, and IL-15 exhibits the broadest reactivation potential across tissues and CD4+ T-cell subsets. These models provide insights into the inducible reservoir's composition in different tissues and inform strategies for its elimination., This study was funded by “la Caixa” Foundation (ID 100010434) under the project code LCF/PR/HR20/00218. This study also received funding from the Agencia Estatal de Investigación project PID2021-123321OB-I00 and PID2024-155881OB-100 supported by MCIN/AEI/10.13039/501100011033/FEDER, UE; The Spanish “Ministerio de Economía y Competitividad, Instituto de Salud Carlos III” (ISCIII, PI20/00160); and the Gilead fellowships GLD21-00049, GLD22/00152 and GLD24/00014. MJB is supported by the Miguel Servet programme of the Spanish Health Institute Carlos III (CP17/00179 and CPII22/00005), and AGC is a recipient of a PhD fellowship from “la Caixa” Foundation (LCF/BQ/DI20/11780014). The funders had no role in the design of the study, data collection or analysis, decision to publish, or manuscript preparation. We acknowledge María Lázaro and Ruth Peña (JGP research group) for their technical assistance in the production of the HIVBAL viral stock.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

KLRG1 expression on natural killer cells is associated with HIV persistence, and its targeting promotes the reduction of the viral reservoir

  • Astorga Gamaza, Antonio
  • Sánchez Gaona, Nerea
  • Calvet-Mirabent, Marta
  • Gallego-Cortés, Ana
  • Rey Cano, Joan
  • Curran, Adrian
  • Grau Exposito, Judith
  • Castellvi, Josep
  • Burgos, Joaquin
  • Navarro, Jordi
  • Suanzes, Paula
  • Genescà Ferrer, Meritxell
  • Buzon, Maria Jose
  • Falcó, Vicenç
  • Perea Pérez, David
HIV infection; HIV reservoir; Immunotherapy, Infección por VIH; Reservorio de VIH; Inmunoterapia, Infecció per VIH; Reservori de VIH; Immunoteràpia, Human immunodeficiency virus (HIV) infection induces immunological dysfunction, which limits the elimination of HIV-infected cells during treated infection. Identifying and targeting dysfunctional immune cells might help accelerate the purging of the persistent viral reservoir. Here, we show that chronic HIV infection increases natural killer (NK) cell populations expressing the negative immune regulator KLRG1, both in peripheral blood and lymph nodes. Antiretroviral treatment (ART) does not reestablish these functionally impaired NK populations, and the expression of KLRG1 correlates with active HIV transcription. Targeting KLRG1 with specific antibodies significantly restores the capacity of NK cells to kill HIV-infected cells, reactivates latent HIV present in CD4+ T cells co-expressing KLRG1, and reduces the intact HIV genomes in samples from ART-treated individuals. Our data support the potential use of immunotherapy against the KLRG1 receptor to impact the viral reservoir during HIV persistence., The project leading to these results has received funding from “la Caixa” Banking Foundation under the project code LCF/PR/HR20-00218. This study was also supported by the Agencia Estatal de Investigación project PID2021-123321OB-I00 funded by MCIN/AEI/10.13039/501100011033/FEDER, UE; The Spanish “Ministerio de Economia y Competitividad, Instituto de Salud Carlos III” (ISCIII, PI20/00160); and the Gilead fellowships GLD19/00084, GLD18/00008, GLD21-00049, and GLD22/00152. Part of the methodology was developed with the support of the grant 202104-30-31 from Fundació la Marató de TV3. M.B. is supported by the Miguel Servet program funded by the Spanish Health Institute Carlos III (CPII22/00005). A.A.-G. was supported by the Spanish Secretariat of Science and Innovation Ph.D. fellowship (BES-2016-076382). D.P. was supported by the VHIR Ph.D programme 2020. Spanish Secretariat of Science and Innovation Ph.D. fellowship. E.M.G. was supported by the Ramón y Cajal Program (RYC2018-024374-I) funded by the Spanish Secretariat of Science and Innovation, by the Comunidad de Madrid Talento Program (2017-T1/BMD-5396), and by the project PID2021-127899OB-I00 funded by MCIN /AEI /10.13039/501100011033/ FEDER, UE. We thank Dr. Joan Puñet from the flow cytometry core at the Vall d’Hebron Research Institute for his technical and scientific expertise. The funders had no role in study design, data collection, and analysis, the decision to publish, or preparation of the manuscript.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Impact of very early antiretroviral therapy during acute HIV infection on long-term immunovirological outcomes

  • Suanzes, Paula
  • Álvarez-López, Patricia
  • García Pérez, Jorge N.
  • Monforte, Arnau
  • Arando Lasagabaster, Maider
  • Rodríguez Vázquez, Lucía
  • Planas Ribas, Bibiana
  • Curran Fàbregas, Adria
  • Navarro, Jordi
  • Rando Segura, Ariadna
  • Descalzo Jorro, Vicente
  • Buzon, Maria Jose
  • Falcó, Vicenç
  • Burgos Cibrian, Joaquin
Acute HIV infection; Antiretroviral treatment; Immune recovery, Infección aguda por VIH; Tratamiento antirretroviral; Recuperación inmunitaria, Infecció aguda per VIH; Tractament antiretroviral; Recuperació immunitària, Objectives We aimed to determine if starting antiretroviral therapy (ART) in the first 30 days after acquiring HIV infection has an impact on immunovirological response. Methods Observational, ambispective study including 147 patients with confirmed acute HIV infection (January/1995-August/2022). ART was defined as very early (≤30 days after the estimated date of infection), early (31-180 days), and late (>180 days). We compared time to viral suppression (viral load [VL] <50 copies/ml) and immune recovery (IR) (CD4+/CD8+ ratio ≥1) according to the timing and type of ART using survival analysis. Results ART was started in 140 (95.2%) patients. ART was very early in 24 (17.1%), early in 77 (55.0%), and late in 39 (27.9%) cases. Integrase strand transfer inhibitor (INSTI)-based regimens were the most used in both the overall population (65%) and the very early ART group (23/24, 95.8%). Median HIV VL and CD4+/CD8+ ratio pre-ART were higher in the very early ART group (P <0.05). Patients in the very early and early ART groups and treated with INSTI-based regimens achieved IR earlier (P <0.05). Factors associated with faster IR were the CD4+/CD8+ ratio pre-ART (hazard ratio: 9.3, 95% CI: 3.1-27.8, P <0.001) and INSTI-based regimens (hazard ratio: 2.4, 95% CI: 1.3-4.2, P = 0.003). Conclusions The strongest predictors of IR in patients who start ART during AHI are the CD4+/CD8+ ratio pre-ART and INSTI-based ART regimens., This work was founded by Instituto de Salud Carlos III (Acción Estratégica en Salud) and Fondo Europeo de Desarrollo Regional (FEDER) through grant PI20/00823. The study was also supported by the Spanish Network for AIDS Research (RIS) through the Instituto de Salud Carlos III – Red Temática de Investigación Cooperativa en Sida (RD06/006, RD12/0017/0018 and RD16/0002/0006) as part of the Plan Nacional R+D+I and by ISCIII Subdirección General de Evaluación and Fondo Europeo de Desarrollo Regional (FEDER). For this project, PS has received a grant from the Catalan Society of Infectious Diseases and Clinical Microbiology (SCMIMC) funded by ViiV Healthcare. MJB is supported by the Miguel Servet program funded by the Spanish Health Institute Carlos III (CPII22/00005). The funders had no role in the study design, data collection, and interpretation, or the decision to submit the work for publication.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Impact of very early antiretroviral therapy during acute HIV infection on long-term immunovirological outcomes

  • Suanzes, Paula
  • Álvarez-López, Patricia
  • García Pérez, Jorge N.
  • Monforte, Arnau
  • Arando Lasagabaster, Maider
  • Rodríguez Vázquez, Lucía
  • Planas Ribas, Bibiana
  • Curran Fàbregas, Adria
  • Navarro, Jordi
  • Rando Segura, Ariadna
  • Descalzo Jorro, Vicente
  • Buzon, Maria Jose
  • Falcó, Vicenç
  • Burgos Cibrian, Joaquin
Acute HIV infection; Antiretroviral treatment; Immune recovery, Infección aguda por VIH; Tratamiento antirretroviral; Recuperación inmunitaria, Infecció aguda per VIH; Tractament antiretroviral; Recuperació immunitària, Objectives We aimed to determine if starting antiretroviral therapy (ART) in the first 30 days after acquiring HIV infection has an impact on immunovirological response. Methods Observational, ambispective study including 147 patients with confirmed acute HIV infection (January/1995-August/2022). ART was defined as very early (≤30 days after the estimated date of infection), early (31-180 days), and late (>180 days). We compared time to viral suppression (viral load [VL] <50 copies/ml) and immune recovery (IR) (CD4+/CD8+ ratio ≥1) according to the timing and type of ART using survival analysis. Results ART was started in 140 (95.2%) patients. ART was very early in 24 (17.1%), early in 77 (55.0%), and late in 39 (27.9%) cases. Integrase strand transfer inhibitor (INSTI)-based regimens were the most used in both the overall population (65%) and the very early ART group (23/24, 95.8%). Median HIV VL and CD4+/CD8+ ratio pre-ART were higher in the very early ART group (P <0.05). Patients in the very early and early ART groups and treated with INSTI-based regimens achieved IR earlier (P <0.05). Factors associated with faster IR were the CD4+/CD8+ ratio pre-ART (hazard ratio: 9.3, 95% CI: 3.1-27.8, P <0.001) and INSTI-based regimens (hazard ratio: 2.4, 95% CI: 1.3-4.2, P = 0.003). Conclusions The strongest predictors of IR in patients who start ART during AHI are the CD4+/CD8+ ratio pre-ART and INSTI-based ART regimens., This work was founded by Instituto de Salud Carlos III (Acción Estratégica en Salud) and Fondo Europeo de Desarrollo Regional (FEDER) through grant PI20/00823. The study was also supported by the Spanish Network for AIDS Research (RIS) through the Instituto de Salud Carlos III – Red Temática de Investigación Cooperativa en Sida (RD06/006, RD12/0017/0018 and RD16/0002/0006) as part of the Plan Nacional R+D+I and by ISCIII Subdirección General de Evaluación and Fondo Europeo de Desarrollo Regional (FEDER). For this project, PS has received a grant from the Catalan Society of Infectious Diseases and Clinical Microbiology (SCMIMC) funded by ViiV Healthcare. MJB is supported by the Miguel Servet program funded by the Spanish Health Institute Carlos III (CPII22/00005). The funders had no role in the study design, data collection, and interpretation, or the decision to submit the work for publication.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Identification of inducible HIV reservoirs in tonsillar, intestinal and cervical tissue models of HIV latency

  • Gallego-Cortés, Ana
  • Sánchez Gaona, PhD, Nerea
  • Ruiz Isant, Oriol
  • Pumarola, Felix
  • Ortiz Laredo, Nuria
  • Llano Espinosa, Ines
  • Mañalich-Barrachina, Laura
  • Mancebo Pérez, Cristina
  • Benítez Martínez, Aleix
  • Landolfi, Stefania
  • Castellvi, Josep
  • Lorente, Juan
  • Falcó, Vicenç
  • Genescà Ferrer, Meritxell
  • Buzon, Maria Jose
HIV; Tissue models; Cellular reservoirs, VIH; Modelos de tejido; Reservorios celulares, VIH; Models de teixit; Reservoris cel·lulars, HIV persists in diverse tissues, with distinct cellular reservoirs presenting a major barrier to a cure and requiring targeted therapeutic strategies to address this heterogeneity. Here, we develop tissue models of HIV latency using human tonsillar, intestinal and cervicovaginal tissues. These models reveal differential HIV infection across CD4+ T-cell subpopulations, with ART partially restoring CD4+ T cells and reducing intact HIV DNA. T follicular helper cells (TFH CD69+ CCR7-) are the primary inducible reservoir in tonsils, while tissue-resident memory cells (TRM CD69+ CD49a+) dominate in the intestine. Identification of markers for inducible reservoirs shows that CD69, CD45RO, and PD-1 are shared across tissues, while CXCR5 in tonsils and CD49a in the intestine act as tissue-specific markers. Furthermore, using different latency reversal agents (LRAs) demonstrates that Histone Deacetylase Inhibitors (HDACis) fail to induce HIV in any tissue, the SMAC mimetic AZD5582 is effective only in a resident-memory CD4+ T-cell subpopulation in the intestine, and IL-15 exhibits the broadest reactivation potential across tissues and CD4+ T-cell subsets. These models provide insights into the inducible reservoir's composition in different tissues and inform strategies for its elimination., This study was funded by “la Caixa” Foundation (ID 100010434) under the project code LCF/PR/HR20/00218. This study also received funding from the Agencia Estatal de Investigación project PID2021-123321OB-I00 and PID2024-155881OB-100 supported by MCIN/AEI/10.13039/501100011033/FEDER, UE; The Spanish “Ministerio de Economía y Competitividad, Instituto de Salud Carlos III” (ISCIII, PI20/00160); and the Gilead fellowships GLD21-00049, GLD22/00152 and GLD24/00014. MJB is supported by the Miguel Servet programme of the Spanish Health Institute Carlos III (CP17/00179 and CPII22/00005), and AGC is a recipient of a PhD fellowship from “la Caixa” Foundation (LCF/BQ/DI20/11780014). The funders had no role in the design of the study, data collection or analysis, decision to publish, or manuscript preparation. We acknowledge María Lázaro and Ruth Peña (JGP research group) for their technical assistance in the production of the HIVBAL viral stock.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Schlafen 12 restricts HIV-1 latency reversal by a codon-usage dependent post-transcriptional block in CD4+ T cells

  • Kobayashi-Ishihara, Mie
  • Frazão Smutná, Katarína
  • Alonso, Florencia E.
  • Argilaguet, Jordi
  • Esteve-Codina, Anna
  • Geiger, Kerstin
  • Genescà Ferrer, Meritxell
  • Grau Exposito, Judith
  • Buzon, Maria Jose
HIV infections; Restriction factors, Infecciones por VIH; Factores de restricción, Infeccions pel VIH; Factors de restricció, Latency is a major barrier towards virus elimination in HIV-1-infected individuals. Yet, the mechanisms that contribute to the maintenance of HIV-1 latency are incompletely understood. Here we describe the Schlafen 12 protein (SLFN12) as an HIV-1 restriction factor that establishes a post-transcriptional block in HIV-1-infected cells and thereby inhibits HIV-1 replication and virus reactivation from latently infected cells. The inhibitory activity is dependent on the HIV-1 codon usage and on the SLFN12 RNase active sites. Within HIV-1-infected individuals, SLFN12 expression in PBMCs correlated with HIV-1 plasma viral loads and proviral loads suggesting a link with the general activation of the immune system. Using an RNA FISH-Flow HIV-1 reactivation assay, we demonstrate that SLFN12 expression is enriched in infected cells positive for HIV-1 transcripts but negative for HIV-1 proteins. Thus, codon-usage dependent translation inhibition of HIV-1 proteins participates in HIV-1 latency and can restrict the amount of virus release after latency reversal., This work was supported by following grants: M.K.I., JSPS Oversea Research Fellowship and Takeda Science Foundation; A.E.C., PT17/0009/0019 (ISCIII/MINECO and FEDER); M.J.B., RTI2018-101082-B-I00 and PID2021-123321OB-I00 [MINECO/FEDER]), and the Miguel Servet program by ISCIII (CP17/00179 and CPII22/00005); C.B., M.R.R., C.D.C., European Union’s Horizon 2020 research and innovation program under grant agreement 681137-EAVI2020 and NIH grant P01-AI131568; J.D., the Spanish Ministry of Science and Innovation (PID2019106959RB-I00/AEI/10.13039/501100011033); A.M., the Spanish Ministry of Science and Innovation (PID2019-106323RB-I00 AEI//10.13039/501100011033) and the institutional “María de Maeztu” Programme for Units of Excellence in R&D (CEX2018-000792-M).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

NK cell depletion in bispecific antibody therapy is associated with lack of HIV control after ART interruption

  • Perea Pérez, David
  • Martin-Gayo, Enrique
  • Zamora Carrillo, Jorge Ivan
  • Sánchez Gaona, Nerea
  • Curran, Adrian
  • Burgos, Joaquin
  • Navarro, Jordi
  • Suanzes, Paula
  • Falcó, Vicenç
  • Genescà Ferrer, Meritxell
  • Buzon, Maria Jose
NK cell; Bispecific antibody therapy; HIV, Cèl·lules NK; Teràpia d'anticossos biespecífics; VIH, Células NK; Terapia d'anticuerpos biespecíficos; VIH:es, HIV infection remains incurable as the virus persists within a latent reservoir of CD4+T cells. Novel approaches to enhance immune responses against HIV are essential for effective control and potential cure of the infection. In this study, we designed a novel tetravalent bispecific antibody (Bi-Ab32/16) to simultaneously target the gp120 viral protein on infected cells, and the CD16a receptor on NK cells. In vitro, Bi-Ab32/16 triggered a potent, specific, and polyfunctional NK-dependent response against HIV-infected cells. Moreover, addition of the Bi-Ab32/16 significantly reduced the latent HIV reservoir after viral reactivation and mediated the clearance of cells harboring intact proviruses in samples from people with HIV (PWH). However, the in vivo preclinical evaluation of Bi-Ab32/16 in humanized mice expressing IL-15 (NSG-Hu-IL-15) revealed a significant decline of NK cells associated with poor virological control after ART interruption. Our study underscores the need to carefully evaluating strategies for sustained NK cell stimulation during ART withdrawal., This study was supported by the Spanish Secretariat of Science and Innovation, FEDER funds (RTI2018-101082-B-I00, PID2021-123321OB-I00, PDC2022.133836-100), two Gilead fellowships (GLD21/00049, GLD22/00152) as well as partially funded by the PI20/00160 grant from the Spanish Health Institute Carlos III, co-funded by ERDF/ESF, “A way to make Europe”/“Investing in your future”, the CNS2022-135549 grant, funded by MCIN/AEI/10.13039/501100011033 and by the European Union «Next Generation EU»/PRTR. M.B. is supported by the Miguel Servet program funded by the Spanish Health Institute Carlos III (CP17/00179 and CPII22/00005). N.S-G is supported by the Spanish Secretariat of Science and Innovation Ph.D. fellowship (PRE2019-087393). We would like to thank Dr. Julia G. Prado from IrsiCaixa Institute for AIDS Research for generating the viral stock R5-BaL and Jorge Díaz from the Comparative Medicine and Bioimage Centre of Catalonia (CMCIB) for its excellent technical assistance with in vivo animal studies. The funders had no role in study design, data collection, and analysis, the decision to publish, or preparation of the manuscript.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

KLRG1 expression on natural killer cells is associated with HIV persistence, and its targeting promotes the reduction of the viral reservoir

  • Astorga Gamaza, Antonio
  • Sánchez Gaona, Nerea
  • Calvet-Mirabent, Marta
  • Gallego-Cortés, Ana
  • Rey Cano, Joan
  • Curran, Adrian
  • Grau Exposito, Judith
  • Castellvi, Josep
  • Burgos, Joaquin
  • Navarro, Jordi
  • Suanzes, Paula
  • Genescà Ferrer, Meritxell
  • Buzon, Maria Jose
  • Falcó, Vicenç
  • Perea Pérez, David
HIV infection; HIV reservoir; Immunotherapy, Infección por VIH; Reservorio de VIH; Inmunoterapia, Infecció per VIH; Reservori de VIH; Immunoteràpia, Human immunodeficiency virus (HIV) infection induces immunological dysfunction, which limits the elimination of HIV-infected cells during treated infection. Identifying and targeting dysfunctional immune cells might help accelerate the purging of the persistent viral reservoir. Here, we show that chronic HIV infection increases natural killer (NK) cell populations expressing the negative immune regulator KLRG1, both in peripheral blood and lymph nodes. Antiretroviral treatment (ART) does not reestablish these functionally impaired NK populations, and the expression of KLRG1 correlates with active HIV transcription. Targeting KLRG1 with specific antibodies significantly restores the capacity of NK cells to kill HIV-infected cells, reactivates latent HIV present in CD4+ T cells co-expressing KLRG1, and reduces the intact HIV genomes in samples from ART-treated individuals. Our data support the potential use of immunotherapy against the KLRG1 receptor to impact the viral reservoir during HIV persistence., The project leading to these results has received funding from “la Caixa” Banking Foundation under the project code LCF/PR/HR20-00218. This study was also supported by the Agencia Estatal de Investigación project PID2021-123321OB-I00 funded by MCIN/AEI/10.13039/501100011033/FEDER, UE; The Spanish “Ministerio de Economia y Competitividad, Instituto de Salud Carlos III” (ISCIII, PI20/00160); and the Gilead fellowships GLD19/00084, GLD18/00008, GLD21-00049, and GLD22/00152. Part of the methodology was developed with the support of the grant 202104-30-31 from Fundació la Marató de TV3. M.B. is supported by the Miguel Servet program funded by the Spanish Health Institute Carlos III (CPII22/00005). A.A.-G. was supported by the Spanish Secretariat of Science and Innovation Ph.D. fellowship (BES-2016-076382). D.P. was supported by the VHIR Ph.D programme 2020. Spanish Secretariat of Science and Innovation Ph.D. fellowship. E.M.G. was supported by the Ramón y Cajal Program (RYC2018-024374-I) funded by the Spanish Secretariat of Science and Innovation, by the Comunidad de Madrid Talento Program (2017-T1/BMD-5396), and by the project PID2021-127899OB-I00 funded by MCIN /AEI /10.13039/501100011033/ FEDER, UE. We thank Dr. Joan Puñet from the flow cytometry core at the Vall d’Hebron Research Institute for his technical and scientific expertise. The funders had no role in study design, data collection, and analysis, the decision to publish, or preparation of the manuscript.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Resident CD49a+CD103+NKG2C+ NK cells restrict HIV infection in human lymphoid tissue explants

  • González Robles, Alba
  • Gallego-Cortés, Ana
  • Ortiz Laredo, Nuria
  • Llano, Ines
  • Perea Pérez, David
  • Sánchez Gaona, PhD, Nerea
  • Pumarola, Felix
  • Lorente, Juan
  • Falcó, Vicenç
  • Genescà Ferrer, Meritxell
  • Buzon, Maria Jose
HIV infection; NK cells, Infección por VIH; Células NK, Infecció per VIH; Cèl·lules NK, Natural killer (NK) cells are pivotal effectors in antiviral immunity, yet their tissue-specific roles during acute HIV infection remain poorly defined. Using an ex vivo human tonsillar tissue model, we profile NK cell responses to early HIV infection and uncover distinct subsets with specialized functions. We identify a previously uncharacterized memory-like NK population (CD16+/−CD69+CD49a+CD103+NKG2C+) associated with reduced viral burden and enriched in cytotoxic mediators (GNLY, PRF1, and GZMB), apoptotic ligands (FASLG and TRAIL), cytokine receptors (IL2RA, IL2RB, IL2RG, IL12RB2, and IL18R1) and trafficking molecules (CCL3–5, CCR7, and SELL). Although functionally capable of clearing HIV-infected CD4+ T cells in a tissue-mimetic environment, they show impaired cytotoxicity and transcriptional signs of exhaustion after infection. Conversely, HIV drives the reprogramming of immature CD16−CD69+ NK cells toward a more cytotoxic and migratory effector phenotype. These findings reveal dynamic NK cell adaptations in lymphoid tissue during early HIV infection and highlight tissue-resident NK cells as promising targets for immunotherapeutic intervention., The project leading to these results has received funding from “la Caixa” Banking Foundation under the project code [LCF/PR/HR20-00218] to M.J.B. This study was supported by the Agencia Estatal de Investigación project PID2021-123321OB-I00 funded by MCIN/AEI/10.13039/501100011033/FEDER, UE to M.J.B.; the Spanish “Ministerio de Economía y Competitividad, Instituto de Salud Carlos III” (ISCIII, PI20/00160) to M.G.; and the Gilead fellowship GLD22/00152 to M.J.B. M.J.B. is supported by the Miguel Servet program funded by the Spanish Health Institute Carlos III (CPII22/00005). D.P. was supported by the VHIR 2020 Ph.D. Fellowship. The funders had no role in study design, data collection, and analysis, the decision to publish, or preparation of the manuscript.